• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Creabilis

edit

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential.

Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis’ pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.

Milestones

edit

• 
  Creabilis added Alex Leech as ice President, Head of Finance and Operations.
  Posted 10/4/11 at 6:23pm
• 
  Creabilis added Eliot Forster as CEO.
  Posted 9/15/10 at 8:23pm
• 
  Creabilis invested in Nautilus Biotech. (4/30/07)
  Posted 3/14/10 at 8:28pm via prnewswire.com
• 
  Creabilis received $20M in Series B funding. (10/4/11)
  Posted 10/4/11 at 6:25pm via creabilis-sa.com

Videos

Screenshots

edit

Above: Creabilis Therapeutics
Uploaded: 3/15/10

Sources

1. Nautilus Biotech Closes EUR8.4 Million ($11.3 Million) Investment Funding (prnewswire.com) [edit]
2. Creabilis Raises €15.0M ($20M) in Series B Fundraising Round (creabilis-sa.com) [edit]